Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250210 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control
A Phase 2 study of Ovulation Suppression, sponsored by Agile Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 11
- Study locations
NCT01250210 is a Phase 2 study of Ovulation Suppression that has completed, run by Agile Therapeutics. The registered enrollment target is 123 participants. The trial reports 11 study locations across 8 states.
The verdict
NCT01250210, a Phase 2 study of Ovulation Suppression, has completed, sponsored by Agile Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 11
- Study locations
Study Summary
Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).
Conditions Studied
Interventions
- DRUG levonorgestrel and ethinyl estradiol
Study Locations (11)
Florida
- - Pembroke Pines
- - Tampa
North Carolina
- - Cary
- - Winston-Salem
Pennsylvania
- - Jenkintown
- - Philadelphia
Arizona
- - Tucson
California
- - San Diego
Colorado
- - Denver
Georgia
- - Sandy Springs
Tennessee
- - Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250210
The ClinicalTrials.gov registry entry for NCT01250210 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agile Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovulation Suppression appearing as the primary indexed condition, and to 1 intervention - of which levonorgestrel and ethinyl estradiol is the first listed.
NCT01250210 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01250210 about?
NCT01250210 is a clinical study titled "Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control". Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).
What is the current status of trial NCT01250210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2007-09. Estimated completion is 2008-02.
What conditions does trial NCT01250210 study?
This clinical trial studies the following conditions: Ovulation Suppression.
What interventions are being tested in trial NCT01250210?
The interventions under investigation include: levonorgestrel and ethinyl estradiol (DRUG).
Who is sponsoring clinical trial NCT01250210?
This trial is sponsored by Agile Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01250210 being conducted?
This trial has 11 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.